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 By 2030, 70% of all pancreatic cancer will be diagnosed in the older population. However, pancreas operations are 
a complex surgical procedure with a high rate of morbidity and mortality. Therefore, the benefits of surgical resection in 
older patients are controversial and decisions about treatment for this group must be well balanced. Chronological age 
alone should not be a contraindication for multimodal radical treatment in older patients. Fit patients, according to the 
comprehensive geriatric assessment (SGA), should be qualified for the same treatment as younger patients to benefit 
the same outcomes. However, they should be operated on in high-volume hospitals by experienced surgeons. Prefrail 
patients should undergo prehabilitation, during neoadjuvant treatment also, and then reevaluated. Frail patients should 
be discussed in an oncogeriatric meeting. We still do not have evidence-based data to design a tailored approach for them 
so as to balanced good oncologic outcomes and the appropriate postoperative quality of life.  
Key words: older patients, pancreatic cancer, pancreatoduodenectomy, elderly
How to cite:
Kenig J, Richter P. Pancreatoduodenectomy due to cancer in the older population. NOWOTWORY J Oncol 2021; 71: 321–327. 
Pancreatic ductal adenocarcinoma (PC) is common in the older 
population, with incidence increasing with age, reaching the 
highest peak after 60 years of age. It is estimated that by 2030, 
approximately 70% of PC will be diagnosed in this group [1]. 
It also has one of the worst prognoses of all malignancies. At 
present, 5-year relative survival is 8% [2] and improvements seen 
for most cancers over the last 20 years, is unfortunately not the 
case for PC and progress remains very slow. Surgical resection is 
the only curative treatment option; it is possible in only 15–20% of 
patients. Even among those who undergo surgery, 5-year survival 
is just 20–25% due to local or metastatic relapse during the first 
two years after resection. Thus, PC has the potential to become 
the second leading cause of cancer-related death before 2030 [3].
Resection of the pancreas (pancreaticoduodenecto-
my, partial or total pancreatectomy) is a complex surgical 
procedure with a high rate of morbidity and mortality. 
Compared with younger patients, many older patients may 
not be good candidates for surgery, and they are less likely 
to receive other treatments. Therefore, the benefits of sur-
gical resection for PC in older patients remain controversial 
and the decision about this treatment in older patients must 
be well balanced. Moreover, the most important problem 
in the treatment of older patients with PC is the underre-
presentation of this population in clinical trials. This results 
in treatment decisions taken for older patients that are 
extrapolated from studies performed on younger patients. 
Although the situation is improving constantly, most of 
the studies still use chronological age, the Karnofsky scale 
or the Eastern Cooperative Oncology Group/ World Health 
Organization scale and not biological age [4].
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Clinical and pathological characteristics of PC in 
older patients
Very little data is available regarding PC in the older population. 
Kamisawa et al.
 
compared the pathologic features of it in older 
and younger patients and found no differences in location, 
stage, grade and local spread, although older patients seem 
to develop fewer hematogenous metastases. Older patients 
may present more diploid tumours or more p53 mutations, 
which are associated with a poorer prognosis [5].
Preoperative assessment and treatment 
decisions
As was mentioned in our previous publications, the popu-
lation of older patients is very heterogeneous in terms of 
co-morbidity, physical reserve, cognitive function and social 
support. Chronological age alone is a poor predictor of cancer 
treatment outcomes and toxicities [6]. Current routine pre-
-operative assessment cannot adequately identify patients at 
risk. Many older adults have unidentified, uncommunicated, 
and therefore unaddressed aging-related conditions that are 
associated with morbidity and early mortality. Therefore, the 
Comprehensive Geriatric Assessment (CGA) was introduced 
to help determine the primary status of the older patient, to 
diagnose frailty syndrome and to identify how to optimise 
the patient’s condition before the start of treatment [7–10]. 
Frailty syndrome (a surrogate of biological age), is defi-
ned as a multisystem reduction in reserve capacity leading 
to shorter life expectancy, higher risk of complications after 
surgery/chemotherapy, higher risk of hospital readmission 
and institutionalisation.  Considering their limited remaining 
lifetime and their postoperative quality of life, the CGA is as 
valuable as the need to cure or remove their cancers. Therefore, 
the International Society of Geriatric Oncology (SIOG) and The 
European Society for Medical Oncology (ESMO) recommends 
the use of the CGA to determine the biological age before the 
beginning of treatment. Rostoft et al. analysed the literature 
regarding the role of the CGA in predicting the outcome in he-
patobiliary and pancreatic surgery among older patients with 
cancer; they concluded that although scarcely investigated, 
frailty and elements from the CGA are  significantly associated 
with negative short- and long-term treatment outcomes in 
older patients with HBP [11]. 
In general, based on the CGA, we can differentiate three 
groups of older patients: 
1. Fit: patients without any deficits in the CGA domains. In 
this group, standard oncologic treatment can be offered 
and postoperative outcomes are comparable to younger 
patients.
2. Pre-frail: patients with one or two deficits in the CGA 
domains. In these patients prehabilitation should be re-
commended to improved resilience to surgical stress by, 
at least, augmenting functional capacity and nutritional 
status before surgery.
3. Frail patients: patients with three or more impaired do-
mains in the CGA. A tailored approach should be discussed 
in a geriatric multidisciplinary team meeting [9].
It is also possible to determine the severity of the frailty 
using the cumulative deficit model for the CGA [10]. Such 
assessments may guide treatment decisions through evalu-
ations of the balance of benefits and risk-factors associated 
with performing or omitting specific oncologic interventions.
To operate or to not operate?
There have been only a few studies that compare the pro-
gnosis of patients with resectable pancreatic cancer be-
tween the surgery and no surgery group. He et al. showed 
that the first group had a significantly higher 5-year OS rate 
(25.0 vs. 2.3%; p < 0.0001) and a higher median survival time 
(24.3 vs. 5.8 months) [12]. Similarly, in the study by Park HM et al., 
surgical resection resulted in better prognosis than the non-
-surgical approach. Only for patients with a high Charlson 
comorbidity index was this approach not beneficial [13]. 
In  turn, Marmor et al. reported that for the overall cohort, 
the median survival rate was significantly longer for patients 
treated with pancreatectomy as compared with chemotherapy 
(15 months vs. 10 months). However, for patients 80 years of 
age and older, the absolute survival benefit was only 3 mon-
ths (13  months vs. 10 months). Similarly, for patients who 
underwent pancreatectomy and had positive lymph nodes, 
the median survival benefit was only 3 months compared to 
chemotherapy (13 months vs. 10 months) [14]. None of the 
studies investigated any elements of the CGA.
To conclude, fit and pre-frail patients based on the CGA, 
should be operated on (the latter group after prehabilitation) 
with no regard for the chronological age. We do not have 
good data to draw a conclusion about what would be most 
beneficial for frail patients in the long-term follow-up. In severe 
frailty, the best support treatment seems the best option.
It surgery safe for older patients?
The most up-dated systematic review and metanalysis on 
pancreatoduodenectomy in older patients was performed by 
Ten E. et al. in 2019. The study included 12 retrospective studies 
with 4860 patients. There were 919 patients in the older group 
and 3941 patients in the younger group. The authors conclu-
ded that pancreatic surgery had become a safe procedure  for 
older patients in high-volume hospitals when operated on by 
an experienced surgeon [15]. 
The general postoperative mortality rate decreased from 
30% in the 1980s to 1% at the present time. However, the 
complication rate remains high at 40–70%.  A similar situation 
is reported in older patients, it does not matter what kind 
of age cut-off was used to define “elderly”. In comparison 
to the younger population, some authors report higher po-
stoperative morbidity and mortality, a higher requirement 
for an intensive care unit stay, increased length of hospital 
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stay and higher rates of hospital readmission after pancre-
atectomy [16–20]. There are also studies reporting lack of 
significant differences between these groups. The reason for 
the significant differences was the volume of the hospital; 
<50 vs. >50 pancreatoduodenectomies per year. Across high 
volume centres, there was no significant difference in the 
rate of overall and major complications between patients 
≥80 years old and <80 years. Higher volume centres also 
had significantly lower in-hospital mortality and failure to 
rescue rates (in some centres even 0%!) when compared to 
lower volume centres. Thus, the increased mortality in older 
patients was attributed to worse preoperative selection and 
higher failure to rescue rates in patients in the older group. 
The three most common causes of failure to rescue were: 
postoperative pneumonia, cardiovascular accidents and po-
stoperative bleeding [21]. Therefore, early recognition and 
timely management of complications  are crucial as regards 
decreasing mortality in older patients.
Specific surgical complications, such as postoperative pan-
creatic fistula, delayed gastric emptying, postpancreatectomy 
hemorrhaging and intraabdominal abscess were comparable 
between the older and younger group [22]. Barabas et al. conc-
luded their study with an observation that older patients who 
can successfully complete the course of neoadjuvant therapy 
and tolerate its associated morbidity probably had adequate 
physiological reserve to withstand the surgery [23].
When it comes to the overall survival of older patients after 
pancreatic resection, it was shorter than younger patients. 
Finlayson observed the 5-year survival of patients following 
surgery for PC  and demonstrated a decrease from 16.4% in 
patients aged 65–69 years to 15.6% in patients aged 70–79 
years and 11.3% in patients aged 80 years or older. However, 
this difference did not achieve statistical significance. Moreover, 
patients with more than two comorbidities had a 5-year-su-
rvival rate of 10% compared with 14% in patients with fewer 
than two comorbidities; the difference was insignificant [24]. 
This was mainly because  older patients did not receive stan-
dard treatment for pancreatic cancer. Older patients were less 
likely to receive a pancreatectomy with concomitant venous 
resection, achieve negative margins after surgical resection 
and receive adjuvant chemotherapy treatment. Moreover, 
older patients might have been excluded, or might have re-
fused standard “aggressive” therapies, which in turn may have 
affected their long-term survival outcomes [25]. 
The limitations of the systematic review were retrospective 
design of the studies, patients with unresectable tumors or 
those who declined or have been declined surgical treatment 
leading to potential selection and information bias. Furthermo-
re, the statistical power of this study was not high.
To conclude, pancreatic resection due to cancer can be 
performed safely in older patients with acceptable risk in 
high-volume centres where operations were performed by 
experienced surgeons. Chronological age alone should not be 
the only determinant for the selection of patients for surgical 
treatment. In fit and pre-frail patients, aggressive surgery is 
recommended to achieve clear surgical margins. However, 
these data have to be confirmed in large prospective studies 
with the consideration of non-operative treatment, particularly, 
when biological age is taken into consideration.  
Minimal invasive surgery in pancreatic cancer 
In 2021, Zhu et al. performed a systematic review and meta-
nalysis of seven retrospective studies involving 2727 patients. 
Three of them compared a minimal invasive pancreaticodu-
odenectomy (MIP) and an open pancreaticoduodenectomy 
(OPD) in older patients, two compared MIP between older 
and young patients and two included both outcomes. Compa-
red to those with OPD, older patients who underwent minimal 
invasive surgery had a lower 90-day mortality (OR 0.56; 95% 
CI: 0.32–0.97; p = 0.04) and less delayed gastric emptying 
(OR  0.54; 95% CI: 0.33–0.88; p = 0.01). On the other hand, 
no significant difference was observed in terms of 30-day 
mortality, major morbidity, postoperative pancreatic fistula 
(grade B/C), postoperative hemorrhaging, reoperations, 30-
day readmissions and operative time. There was no significant 
difference in operative time between MIP and OPD after the 
learning curve in case of early cancer stage [26]. However, 
we have to be aware that most of the studies included in the 
metanalysis had significant selection bias regarding who was 
a candidate for minimal invasive surgery; excluding those 
patients with larger tumours, vascular involvement and prior 
surgery. Most of the studies were underpowered. Long-term 
outcomes, such as overall survival and disease-free survival, 
were not systematically reported [27, 28].
To conclude, this meta-analysis demonstrates that MIPD is 
a safe and feasible procedure for select older patients if perfor-
med by experienced surgeons from high-volume pancreatic 
surgery centres. Older patients can benefit from the advan-
tages of minimal invasive surgery in the case of uneventful 
postoperative course [29].
Quality of life after PD
All studies showed a deterioration in patient-reported out-
comes and functions after a pancreatoduodenectomy. They 
were at their worst level after 6 weeks after the resection. Most 
of the symptoms abated after 3 months and function after 
6 months when adjuvant chemotherapy was not introduced. 
Quality of life has been shown to recover 12 months from 
potentially curative surgery [30]. In turn, body weight, triceps 
skin-fold thickness and  serum albumin levels recovered in 
the following 3–6 months [31, 32]. In 33–55% of all studied 
patients with PC, depression was observed; this was signifi-
cantly higher than in patients with other malignancies [33]. 
Diouf et al. identified fatigue, appetite loss and functioning 
as the most important aspects of quality of life in predicting 
prognosis [34].
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OS in the older population (HR: 1.89; CI: 1.27–2.78; p = 0.002). 
Patients at the age of ≥70 years of age who received adjuvant 
treatment had a survival benefit of the same magnitude as 
younger patients (21.8 vs. 22.5 months) [41].
Neoadjuvant therapies have been introduced with the aim 
of downstaging the tumour in order to improve microscopic 
resection rates. Older patients, with borderline or resectable 
pancreatic cancer in which the initiation of adjuvant chemo-
therapy is frequently delayed due to surgical complications, co-
morbidities and general health status could particularly benefit 
from this approach. Preoperative therapies also provide a time 
window allowing not only a clear view of the “ugly” biology 
of the cancer but also a chance to carry out the multimodal 
prehabilitation of pre- and frail patients. Barabas et al. observed 
that older patients who can successfully complete a course 
of neoadjuvant therapy and tolerate its associated morbidity 
probably had adequate physiological reserve to withstand 
surgery. In turn, Miura et al. reported the outcomes associated 
with neoadjuvant therapy (chemotherapy or chemoradiothe-
rapy) in older patients with resectable or borderline resectable 
pancreatic cancer. The authors showed that the 75+ group 
compared with the younger group had more hospitalisations 
during the therapy (50 vs. 28%) and were also less likely to 
complete the therapy (72.4 vs. 89.5%). However, among the 
patients who completed the therapy, there were no significant 
differences in complication rates or median overall survival 
between the two groups. In turn, Marmor et al. showed that, 
compared with chemotherapy, surgical resection is associated 
with a very small survival advantage in older patients (aged 
≥80 years with lymph node metastasis) [42].
In conclusion, the neoadjuvant approach seems to be an 
attractive treatment option in older patients with borderline 
resectable pancreatic cancer and for patients who are not 
candidates for surgery, allowing also for prerehabilitation 
and reevaluation possibilities. The role of adjuvant therapy 
has been demonstrated to be beneficial, however, older 
patients are often not included due to longer postoperative 
recovery and subjective evaluation of the patient’s health 
status or life expectancy. We urgently need well-designed 
In the long-term evaluation, the quality of life of patients 
who had remained recurrence-free following surgery for PC, 
was generally good within 24 months of follow-up. Between 
24% and 69% of patients may develop fat-soluble vitamin and 
mineral deficiencies, dumping syndrome, diabetes mellitus 
and delayed gastric emptying [35].
Adjuvant / neoadjuvant treatment
There is still an under representation of older patients in clinical 
trials evaluating the role of perioperative treatment. Therefore, 
it is impossible to draw evidence-based conclusions on the 
optimal treatment model, not to mention the treatment of frail 
patients [36]. Adjuvant therapy includes systemic chemothera-
py to reduce the risk of distant metastases (80% of cases) and 
chemoradiotherapy to reduce the risk of locoregional failure 
(20% of cases). European guidelines favour chemotherapy 
alone and do not recommend the use of chemoradiotherapy 
outside of a clinical trial setting. In the United States, guidelines 
recommend chemoradiotherapy as a suitable alternative to 
adjuvant chemotherapy alone [37]. 
Based on mainly retrospective studies, it can be concluded 
that despite the repeatedly demonstrated benefits of adjuvant 
treatment (increasing 5-year overall survival by up to 25%, 
independently of age), multimodal therapy seems to be un-
derutilised in the older population [38]. Parmar et al.
 
showed 
that only 11% of over 10 thousand studied patients older than 
65 years with PC received surgery and chemotherapy. Taking 
into consideration the whole population, less than half of pa-
tients undergoing resection received chemotherapy [39]. In the 
older group, this could be due to longer postoperative recovery 
and the subjective perception of the limited life expectancy 
of patients with PC, considering mainly the chronological age, 
the ASA or ECOG/WHO scale. However, available data shows 
that older patients may benefit from chemotherapy in both 
adjuvant and advanced disease settings. Despite the discor-
dant results, gemcitabine-based treatment and dose-adapted 
fluorouracil combination regimens seem to be effective and 
well tolerated in this subset of patients [40]. Not receiving 
chemotherapy was an independent prognostic factor for poor 
Table I. Therapeutic options for pancreatic cancer depending on the cancer stage, including options for frail older patients
Stage factors Fit patients Frail patients 
resectable pancreatic 
cancer
surgery ⟶ adjuvant chemotherapy • prehabilitation + reevaluation ⟶ surgery
• neoadjuvant chemotherapy (in the meantime +/– prehabilitation)  ⟶ 
surgery
• best supportive care in severe frailty
border-line resectability preoperative chemotherapy + reevaluation 
⟶ surgery ⟶ postoperative chemotherapy
• neoadjuvant chemotherapy (in the meantime +/– prehabilitation)  ⟶ 
surgery
• palliative treatment





• best supportive care 
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prospective studies evaluating their role in the treatment 
of the older population with PC. However, the basis for the 
selection of patients must be biological and not chronolo-
gical age [43–45].
Palliative treatment
There are only few studies dedicated to older patients. In the 
prospective PRODIGE clinical trial, age was an adverse pro-
gnostic factor in metastatic PC [46]. In other studies, the use 
of systemic therapy was proven to have a survival benefit in 
selected old and very old patients [47]. Considering the results 
of published studies, Higuera et al. proposed the following 
treatment for older patients with metastatic PC [48]: 
1. Patients <75 years old:
• ECOG 0–1: FOLFIRINOX or gemcitabine-nab-paclitaxel 
schedule,
• ECOG 2:  nab-paclitaxel-gemcitabine, 
• ECOG 2 or more: best supportive care. 
2. Patients >75 years old:
• ECOG 0–2: gemcitabine-nab-paclitaxel schedule,
• ECOG >2: best supportive care.
Best supportive care
At the time of diagnosis, the majority of patients had a locally 
advanced PC or metastatic disease characterised by a high 
symptom burden. The most common complications obse-
rved in patients with PC are: cachexia (80%; due to complex 
pathophysiological processes), pain (75%; due to pancreatic 
and celiac plexus infiltration), biliary obstruction (70%; in case 
of head location), duodenal obstruction (20%), and thrombo-
embolic events.
Cachexia is characterised by the loss of skeletal muscle 
mass that cannot be fully reversed via conventional nutritional 
support and leads to progressive functional impairments. This 
state is therefore particularly dangerous for older patients, very 
often influencing the decision regarding further treatment. 
Weight stabilisation in patients with PDAC has been associated 
with improved OS and quality of life [49]. 
Older patients usually underreport pain. Thus, it remains 
not poorly treated, leading to a decrease in the quality of 
life, depression and a deterioration of performance status 
[50]. Biliary obstruction can be treated successfully with an 
endoscopically placed stent. However, in the case of a plastic 
stent, older age was found to be an unfavourable prognostic 
factor for stent patency [51]. In the case of duodenal ob-
struction, stent placement or palliative surgery will resolve 
the symptoms [52]. 
Conclusions
Chronological age alone should not be a contraindication 
for multimodal radical treatment in older patients. The frailty 
(a surrogate of biological age) evaluation should be the basis 
for a discussion on treatment planning. At present, it is one of 
the most reliable factors in older patients. 
Therefore, before treatment begins, the following qu-
estions should be discussed:
• Is the currently planned treatment strategy correct? Are 
there any alternative treatment options? 
• What is the result of the Comprehensive Geriatric Asses-
sment? Can frailty syndrome be diagnosed in the patient? 
• What are the risk of complications? 
• What would be the patient’s lifespan without treatment? 
• What are the goals, preferences and expectations of the 
patient? What effect might treatment have on these goals? 
• Is it possible to improve the patient’s state prior to the 
surgical procedure? 
Surgical resection is the only curative treatment option for 
PC and pancreas surgery has become a safe procedure for older 
patients in high-volume hospitals when operated on by an 
experienced surgeon. Fit and pre-frail (after prehabilitation) pa-
tients, according to the Comprehensive Geriatric Assessment, 
should be qualified for the same treatment as younger patients. 
Frail patients should be discussed in an oncogeriatric meeting. 
We do not have good data to draw a conclusion regarding 
what would be the most beneficial for this subpopulation of 
older patients both in the short- and long-term follow-up. In 
the case of severe frailty, best supportive treatment can be 
the best option. 
The goal of the modifications should be a reduction in 
surgical stress, since in older patients, the pathological outco-
me and postoperative complications are the most important 
predictors of survival. Therefore, preoperative CGA in older 
patients is not the end of geriatric intervention, but merely 
the beginning.
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